Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

INSANE: Looking into tarsus pharmaceuticals s return on capital employed | Rare Historical Photos

According to Benzinga Pro data, during Q4, Tarsus Pharmaceuticals (NASDAQ:TARS) posted sales of $338.00 thousand. Earnings were up 5.39%, but Tarsus Pharmaceuticals still reported an overall loss of $14.85 million. Tarsus Pharmaceuticals collected $1.24 million in revenue during Q3, but reported earnings showed a $15.70 million loss.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.